Literature DB >> 8938559

A case of tizanidine-induced hepatic injury.

E M de Graaf1, M Oosterveld, T Tjabbes, B H Stricker.   

Abstract

The case history is presented of a woman who developed serious liver injury while taking 36 mg tizanidine daily. Other causes of hepatic injury were excluded. Symptoms resolved after discontinuation of tizanidine, and the liver enzyme levels were nearly normal 6 weeks after discontinuation of the drug. Rechallenge with 4 mg tizanidine caused a relapse. The temporal relationship between the symptoms and liver enzyme elevations, the absence of other potential causes, and the reaction to rechallenge, strongly implicate tizanidine as the cause of hepatic injury. As we are not aware of similar case histories, this seems to be the first reported case of tizanidine-induced hepatic injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938559     DOI: 10.1016/s0168-8278(96)80252-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

Review 1.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

2.  Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Authors:  Herbert R Henney; Michael Chez
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

3.  A fatal case of daclizumab-induced liver failure in a patient with MS.

Authors:  Mark Stettner; Catharina C Gross; Anne K Mausberg; Refik Pul; Andreas Junker; Hideo A Baba; Andreas Schulte-Mecklenbeck; Heinz Wiendl; Christoph Kleinschnitz; Sven G Meuth
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-01-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.